Antigrowth factor strategies.
Myers
C
C
Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD 20892.
Trepel
J
J
Sartor
O
O
Cooper
M
M
Ranson
M
M
Toko
T
T
Linehan
M W
MW
D017209:Apoptosis / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D005109:Extracellular Matrix / Q000502:physiology; D006131:Growth Inhibitors / Q000627:therapeutic use*; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D011983:Receptors, Purinergic / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology; D013498:Suramin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*
D006131:Growth Inhibitors; D006133:Growth Substances; D011983:Receptors, Purinergic; D013498:Suramin; D017430:Prostate-Specific Antigen